Lausanne, Switzerland–based Distalmotion already holds FDA de novo approval for Dexter for adult inguinal hernia repair. This marks the second approved indication for the surgical robot in the U.S.

“Cholecystectomy is a key procedure in general surgery, with approximately 1 million cases performed annually — of which 60% are performed in outpatient settings,” said Greg Roche, CEO of Distalmotion. “With indications for inguinal hernia repair and now cholecystectomy, we’re meaningfully building the reach of Dexter in the U.S. so that more surgical teams and patients will benefit from robotic surgery. Our mission remains focused on empowering access to robotics with the right robot for the right site of care.”